Finally, NSCLC patients, with other driver gene changes or EGFR uncommon mutations, or patients of other kinds of cancer with gene mutations also have the problem of “optimal treatment,” which needs to be further studied by clinical workers and researchers. Here, EGFR is linked to non-small cell lung carcinoma.